Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07786168 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07786168 · ClinicalTrials.gov record · last posted 2026-08-26

Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy

Name: Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy — clinical trial record (NCT07786168)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhaseNot applicable

SponsorHanzla Arshad

Started2025-12-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This randomized controlled trial compared roxadustat with erythropoietin for the treatment of anaemia in patients with diabetic nephropathy and chronic kidney disease. A total of 64 patients aged 18 to 75 years were enrolled at the Department of Nephrology, Sheikh Zayed Hospital, Lahore, and randomly assigned in a 1:1 ratio to two treatment groups. Participants in the roxadustat group received roxadustat 100 mg orally three times per week, while participants in the erythropoietin group received recombinant erythropoietin 4000 IU subcutaneously twice weekly. Participants were followed for three months. The primary objective was to compare the change in haemoglobin level between the two treatment groups after treatment.

Trial Details

NCT Number	NCT07786168
Lead Sponsor	Hanzla Arshad
Conditions	Diabetic Nephropathy, Anemia, Chronic Kidney Disease
Enrollment	64 participants
Start Date	2025-12-20
Primary Completion	2026-06-20 (estimated)
Study Completion	2026-06-20 (estimated)
Updated on ClinicalTrials.gov	2026-08-26